Akari Therapeutics says AKTX-101 shows anti-tumor activity in preclinical urothelial cancer models

Reuters2026/08/18 12:53

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Akari reported new preclinical urothelial cancer data for AKTX-101, a TROP2-targeted ADC using its PH1 RNA splicing modulator payload.
AKTX-101 showed statistically significant tumor growth inhibition in the UM-UC-14 metastatic urothelial carcinoma model where Padcev had limited response.
Switching Trodelvy-resistant tumors to AKTX-101 slowed growth, supporting activity in topoisomerase I payload-resistant disease.
Results bolster a differentiated ADC sequencing strategy as prior exposure increases, targeting resistance seen with microtubule or topoisomerase I payloads.
IND-enabling work continues, with a Phase 1 trial start targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180853PRIMZONEFULLFEED9811676) on August 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Akari Therapeutics says AKTX-101 shows anti-tumor activity in preclinical urothelial cancer models

You may also like

Crypto prices